The current status of drug discovery against the human kinome.
暂无分享,去创建一个
[1] R. Talanian,et al. Current in vitro kinase assay technologies: the quest for a universal format. , 2008, Current drug discovery technologies.
[2] T. Waldmann,et al. Preassembly of interleukin 2 (IL-2) receptor subunits on resting Kit 225 K6 T cells and their modulation by IL-2, IL-7, and IL-15: a fluorescence resonance energy transfer study. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[3] A. Newton,et al. Targeting Protein Kinase C Activity Reporter to Discrete Intracellular Regions Reveals Spatiotemporal Differences in Agonist-dependent Signaling* , 2006, Journal of Biological Chemistry.
[4] John D. Scott,et al. A-kinase anchoring proteins and neuronal signaling mechanisms. , 2003, Genes & development.
[5] John D. Scott,et al. High-affinity AKAP7delta-protein kinase A interaction yields novel protein kinase A-anchoring disruptor peptides. , 2006, The Biochemical journal.
[6] A. Ullrich,et al. Growth factor signaling by receptor tyrosine kinases , 1992, Neuron.
[7] M. Karin,et al. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. , 1997, The New England journal of medicine.
[8] Mason R. Mackey,et al. Cloning and mitochondrial localization of full-length D-AKAP2, a protein kinase A anchoring protein , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[9] R. Eglen,et al. A Generic, Homogenous Method for Measuring Kinase and Inhibitor Activity via Adenosine 5′-Diphosphate Accumulation , 2006, Journal of biomolecular screening.
[10] Paul Greengard,et al. Pharmacological inhibitors of cyclin-dependent kinases. , 2002, Trends in pharmacological sciences.
[11] G. Peters,et al. Lack of cyclin D‐Cdk complexes in Rb‐negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product. , 1995, The EMBO journal.
[12] Michael W Parker,et al. Model for growth hormone receptor activation based on subunit rotation within a receptor dimer , 2005, Nature Structural &Molecular Biology.
[13] G. Mathis. HTRF® Technology , 1999 .
[14] T. Okabe,et al. High-throughput screening with quantitation of ATP consumption: a universal non-radioisotope, homogeneous assay for protein kinase. , 2004, Assay and drug development technologies.
[15] M. Meier,et al. Protein kinase C activation and its pharmacological inhibition in vascular disease , 2000, Vascular medicine.
[16] S. Millis,et al. Development and validation of a fluorescence technology for both primary and secondary screening of kinases that facilitates compound selectivity and site-specific inhibitor determination. , 2004, Assay and drug development technologies.
[17] J. Whitney. Reference systems for kinase drug discovery: chemical genetic approaches to cell-based assays. , 2004, Assay and drug development technologies.
[18] Tullio Pozzan,et al. Discrete Microdomains with High Concentration of cAMP in Stimulated Rat Neonatal Cardiac Myocytes , 2002, Science.
[19] R. Frank. Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors. , 2002, American journal of ophthalmology.
[20] E. Sausville,et al. Issues and progress with protein kinase inhibitors for cancer treatment , 2003, Nature Reviews Drug Discovery.
[21] Brad A. Chadwell,et al. Protein Kinases C Translocation Responses to Low Concentrations of Arachidonic Acid* , 2001, The Journal of Biological Chemistry.
[22] L. Tong,et al. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket , 1997, Nature Structural Biology.
[23] N. Pavletich,et al. Structural basis of inhibition of CDK-cyclin complexes by INK4 inhibitors. , 2000, Genes & development.
[24] P. Greengard,et al. Protein phosphorylation in the brain , 1980, Nature.
[25] G. Bemis,et al. Kinase chemogenomics: targeting the human kinome for target validation and drug discovery. , 2004, Mini reviews in medicinal chemistry.
[26] Daria Mochly-Rosen,et al. Adaptor proteins in protein kinase C-mediated signal transduction , 2001, Oncogene.
[27] J. Gutkind. The Pathways Connecting G Protein-coupled Receptors to the Nucleus through Divergent Mitogen-activated Protein Kinase Cascades* , 1998, The Journal of Biological Chemistry.
[28] J. Boehm,et al. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. , 2000, Arthritis and rheumatism.
[29] M. Caron,et al. Beta-adrenergic receptor kinase: identification of a novel protein kinase that phosphorylates the agonist-occupied form of the receptor. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[30] J W Yates,et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. , 2000, Chemistry & biology.
[31] M. Karin,et al. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. , 2001, The Journal of clinical investigation.
[32] Christian Eggeling,et al. Fluorescence intensity and lifetime distribution analysis: toward higher accuracy in fluorescence fluctuation spectroscopy. , 2002, Biophysical journal.
[33] B. Zimmermann,et al. Biomolecular interaction analysis in functional proteomics , 2006, Journal of Neural Transmission.
[34] J. Sportsman,et al. Immobilized metal ion affinity-based fluorescence polarization (IMAP): advances in kinase screening. , 2004, Assay and drug development technologies.
[35] D. Faller,et al. Butyrate-induced G1 arrest results from p21-independent disruption of retinoblastoma protein-mediated signals. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[36] T. Sawyer. Novel oncogenic protein kinase inhibitors for cancer therapy. , 2004, Current medicinal chemistry. Anti-cancer agents.
[37] J. Uney,et al. Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[38] M. Caron,et al. A β-Arrestin/Green Fluorescent Protein Biosensor for Detecting G Protein-coupled Receptor Activation* , 1997, The Journal of Biological Chemistry.
[39] P. N. Rao,et al. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.
[40] A. Ullrich,et al. Growth factor receptor tyrosine kinases. , 1988, Annual review of biochemistry.
[41] T. Spicer,et al. Comparison of Miniaturized Time-Resolved Fluorescence Resonance Energy Transfer and Enzyme-Coupled Luciferase High-Throughput Screening Assays to Discover Inhibitors of Rho-Kinase II (ROCK-II) , 2008, Journal of biomolecular screening.
[42] Yi Liu,et al. Identification of coumarin derivatives as a novel class of allosteric MEK1 inhibitors. , 2005, Bioorganic & medicinal chemistry letters.
[43] M. Caron,et al. Beta-adrenergic receptor kinase: primary structure delineates a multigene family. , 1989, Science.
[44] B. Druker,et al. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. , 2003, Blood.
[45] C. James,et al. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. , 2000, Cancer research.
[46] B. Druker,et al. STI571 (Gleevec) as a paradigm for cancer therapy. , 2002, Trends in molecular medicine.
[47] F. Herberg,et al. Application of Bioluminescence Resonance Energy Transfer (BRET) for Biomolecular Interaction Studies , 2006, Chembiochem : a European journal of chemical biology.
[48] M. Goldman,et al. Structure–Activity Relationship Studies of Ethyl 2-[(3-Methyl-2,5-dioxo(3-pyrrolinyl))amino]-4-(trifluoromethyl)pyrimidine-5-carboxylate: An Inhibitor of AP-1 and NF-κB Mediated Gene Expression , 2002 .
[49] J. Warwicker,et al. The RACK1 scaffold protein: a dynamic cog in cell response mechanisms. , 2002, Molecular pharmacology.
[50] John Kuriyan,et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). , 2001, Cancer research.
[51] S. Knuutila,et al. DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. , 1998, The American journal of pathology.
[52] J. Smolen,et al. Therapeutic strategies for rheumatoid arthritis , 2003, Nature Reviews Drug Discovery.
[53] R. Eglen. Enzyme fragment complementation: a flexible high throughput screening assay technology. , 2002, Assay and drug development technologies.
[54] G. Shen. Selective protein kinase C inhibitors and their applications. , 2003, Current drug targets. Cardiovascular & haematological disorders.
[55] P. Ping,et al. Transgenic Overexpression of Constitutively Active Protein Kinase C ε Causes Concentric Cardiac Hypertrophy , 2000 .
[56] J. Beckmann,et al. Homogeneous and Nonradioactive High-Throughput Screening Platform for the Characterization of Kinase Inhibitors in Cell Lysates , 2006, Journal of biomolecular screening.
[57] Roy Kk,et al. Early Development of Cyclin Dependent Kinase Modulators , 2001 .
[58] J. Sebolt-Leopold,et al. Targeting the mitogen-activated protein kinase cascade to treat cancer , 2004, Nature Reviews Cancer.
[59] D. Zaller,et al. Structural basis for p38α MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity , 2003, Nature Structural Biology.
[60] A. Ambrósio,et al. Old and new drug targets in diabetic retinopathy: from biochemical changes to inflammation and neurodegeneration. , 2005, Current drug targets. CNS and neurological disorders.
[61] J. Pouysségur,et al. Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling. , 2003, Biochemical pharmacology.
[62] Burkhard Haefner,et al. NF-κB: arresting a major culprit in cancer , 2002 .
[63] A. Goldfine,et al. Inhibition of Protein Kinase C&bgr; Prevents Impaired Endothelium-Dependent Vasodilation Caused by Hyperglycemia in Humans , 2002, Circulation research.
[64] A. Thor,et al. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[66] R. Seethala,et al. A fluorescence polarization competition immunoassay for tyrosine kinases. , 1998, Analytical biochemistry.
[67] N. Hayward,et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma , 1996, Nature Genetics.
[68] J. Simard,et al. Transforming Growth Factor-β1 Regulates Kir2.3 Inward Rectifier K+ Channels via Phospholipase C and Protein Kinase C-δ in Reactive Astrocytes from Adult Rat Brain* , 2002, The Journal of Biological Chemistry.
[69] N. Pavletich. Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. , 1999, Journal of molecular biology.
[70] C. Marshall,et al. How do small GTPase signal transduction pathways regulate cell cycle entry? , 1999, Current opinion in cell biology.
[71] F. White,et al. Phosphoproteomic analysis of rat liver by high capacity IMAC and LC-MS/MS. , 2006, Journal of proteome research.
[72] Laura D Miller,et al. RACK1 regulates Src-mediated Sam68 and p190RhoGAP signaling , 2004, Oncogene.
[73] H. Blau,et al. Structural and Mechanistic Insights into Nerve Growth Factor Interactions with the TrkA and p75 Receptors , 2007, Neuron.
[74] Michael Karin,et al. The IKK NF-κB system: a treasure trove for drug development , 2004, Nature Reviews Drug Discovery.
[75] René Hen,et al. Decreased nuclear β‐catenin, tau hyperphosphorylation and neurodegeneration in GSK‐3β conditional transgenic mice , 2001 .
[76] Roger Y. Tsien,et al. A genetically encoded fluorescent reporter reveals oscillatory phosphorylation by protein kinase C , 2003, The Journal of cell biology.
[77] Y. Nishizuka. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. , 1992, Science.
[78] R. Eglen,et al. A High-Throughput, Nonisotopic, Competitive Binding Assay for Kinases Using Nonselective Inhibitor Probes (ED-NSIP™) , 2002, Journal of biomolecular screening.
[79] S. Rotenberg,et al. Photoinduced Inactivation of Protein Kinase C by Dequalinium Identifies the RACK-1-binding Domain as a Recognition Site* , 1998, The Journal of Biological Chemistry.
[80] K. Yeow,et al. Cellular imaging in drug discovery , 2006, Nature Reviews Drug Discovery.
[81] X. P. Liu,et al. Rational design of potent and selective EGFR tyrosine kinase inhibitors as anticancer agents. , 2001, Current cancer drug targets.
[82] M. Caron,et al. Light-dependent phosphorylation of rhodopsin by β-adrenergic receptor kinase , 1986, Nature.
[83] Michael Karin,et al. NF-κB at the crossroads of life and death , 2002, Nature Immunology.
[84] G. Wiche,et al. Plectin-RACK1 (Receptor for Activated C Kinase 1) Scaffolding , 2004, Journal of Biological Chemistry.
[85] J. Chang-Claude,et al. Association of a common AKAP9 variant with breast cancer risk: a collaborative analysis. , 2008, Journal of the National Cancer Institute.
[86] Michael S. Deal,et al. Activation mechanism of CDK2: role of cyclin binding versus phosphorylation. , 2002, Biochemistry.
[87] L. Makings,et al. A FRET-based assay platform for ultra-high density drug screening of protein kinases and phosphatases. , 2002, Assay and drug development technologies.
[88] S. Ghosh,et al. Selective inhibition of NF-κB activation by a peptide that blocks the interaction of NEMO with the IκB kinase complex , 2000 .
[89] Johannes Ottl,et al. Readout Technologies for Highly Miniaturized Kinase Assays Applicable to High-Throughput Screening in a 1536-Well Format , 2006, Journal of biomolecular screening.
[90] K. Gibson,et al. Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. , 2001, Bioorganic & medicinal chemistry letters.
[91] I. McLay,et al. The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy. , 2001, Bioorganic & medicinal chemistry.
[92] K. Lipson,et al. Measurement of the protein tyrosine kinase activity of c-src using time-resolved fluorometry of europium chelates. , 1996, Analytical biochemistry.
[93] Wei-guo Zhang,et al. Identification and characterization of a constitutively T-loop phosphorylated and active recombinant S6K1: expression, purification, and enzymatic studies in a high capacity non-radioactive TR-FRET Lance assay. , 2006, Protein expression and purification.
[94] Mindy I. Davis,et al. A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.
[95] Holger Wesche,et al. High throughput screening for protein kinase inhibitors. , 2005, Combinatorial chemistry & high throughput screening.
[96] D. Goodlett,et al. Identification of phosphorylation sites using microimmobilized metal affinity chromatography. , 2005, Methods in enzymology.
[97] W. Kolch,et al. Targeting MAPK signalling: Prometheus' fire or Pandora's box? , 2004, Current pharmaceutical design.
[98] H. K. Sluss,et al. Selective interaction of JNK protein kinase isoforms with transcription factors. , 1996, The EMBO journal.
[99] D E Griswold,et al. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. , 1996, The Journal of pharmacology and experimental therapeutics.
[100] Y. Shigeri,et al. Recent advances in technologies for analyzing protein kinases. , 2007, Journal of pharmacological sciences.
[101] Diabetes: the latest developments in inhibitors, insulin sensitisers, new drug targets and novel approaches , 2005, Expert opinion on therapeutic targets.
[102] Michael Karin,et al. A central role for JNK in obesity and insulin resistance , 2002, Nature.
[103] Roger L. Williams,et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. , 2000, Molecular cell.
[104] M. Caron,et al. Beta-agonist- and prostaglandin E1-induced translocation of the beta-adrenergic receptor kinase: evidence that the kinase may act on multiple adenylate cyclase-coupled receptors. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[105] Jürg Zimmermann,et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.
[106] R. Eglen,et al. Beta galactosidase enzyme fragment complementation as a novel technology for high throughput screening. , 2003, Combinatorial chemistry & high throughput screening.
[107] E. Nishida,et al. Dynamics of the Ras/ERK MAPK Cascade as Monitored by Fluorescent Probes* , 2006, Journal of Biological Chemistry.
[108] Jos Joore,et al. Kinome Profiling for Studying Lipopolysaccharide Signal Transduction in Human Peripheral Blood Mononuclear Cells* , 2004, Journal of Biological Chemistry.
[109] A. Edelman,et al. Protein serine/threonine kinases. , 1987, Annual review of biochemistry.
[110] D. Onichtchouk,et al. Inhibition of GSK3 Promotes Replication and Survival of Pancreatic Beta Cells* , 2007, Journal of Biological Chemistry.
[111] R. Eglen,et al. A homogeneous cell-based assay to measure nuclear translocation using beta-galactosidase enzyme fragment complementation. , 2006, Assay and drug development technologies.
[112] F. Uckun,et al. Tyrosine kinases as new molecular targets in treatment of inflammatory disorders and leukemia. , 2004, Current pharmaceutical design.
[113] L. Toledo,et al. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. , 2000, Structure.
[114] S. Michnick,et al. Clonal selection and in vivo quantitation of protein interactions with protein-fragment complementation assays. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[115] Jesús Avila,et al. Glycogen synthase kinase 3: a drug target for CNS therapies , 2004, Journal of neurochemistry.
[116] David W. Anderson,et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[117] Michael J. Ackerman,et al. Mutation of an A-kinase-anchoring protein causes long-QT syndrome , 2007, Proceedings of the National Academy of Sciences.
[118] T. Issad,et al. Monitoring the activation state of the insulin receptor using bioluminescence resonance energy transfer. , 2001, Molecular pharmacology.
[119] Nguyen-Huu Xuong,et al. Crystal Structure of a Complex Between the Catalytic and Regulatory (RIα) Subunits of PKA , 2005, Science.
[120] D. M. Olive,et al. Quantitative methods for the analysis of protein phosphorylation in drug development , 2004, Expert review of proteomics.
[121] E. Murphy. Inhibit GSK-3 or theres heartbreak dead ahead , 2004 .
[122] D. Mochly‐Rosen,et al. Identification of intracellular receptor proteins for activated protein kinase C. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[123] W. Fantl,et al. Signalling by receptor tyrosine kinases. , 1993, Annual review of biochemistry.
[124] T. Hunter,et al. The Protein Kinase Complement of the Human Genome , 2002, Science.
[125] H. Blau,et al. A system for quantifying dynamic protein interactions defines a role for Herceptin in modulating ErbB2 interactions , 2006, Proceedings of the National Academy of Sciences.
[126] A. Manning,et al. Transcription inhibitors in inflammation. , 1997, Expert opinion on investigational drugs.
[127] M. Hepperle,et al. A Selective Small Molecule IκB Kinase β Inhibitor Blocks Nuclear Factor κB-Mediated Inflammatory Responses in Human Fibroblast-Like Synoviocytes, Chondrocytes, and Mast Cells , 2006, Journal of Pharmacology and Experimental Therapeutics.
[128] K. McIntyre,et al. A highly selective inhibitor of I kappa B kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice. , 2003, Arthritis and rheumatism.
[129] M. Dowsett,et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.
[130] P. Broad,et al. Identification of kinase inhibitors by an ATP depletion method. , 2004, Assay and drug development technologies.
[131] Frank H Büttner,et al. Miniaturization and Validation of a High-Throughput Serine Kinase Assay Using the Alpha Screen Platform , 2004, Journal of biomolecular screening.
[132] R. Jockers,et al. Activation of the Leptin Receptor by a Ligand-induced Conformational Change of Constitutive Receptor Dimers* , 2003, Journal of Biological Chemistry.
[133] M. Pallàs,et al. Flavopiridol: an antitumor drug with potential application in the treatment of neurodegenerative diseases. , 2005, Medical hypotheses.
[134] J. Hermes,et al. Detection of p56lck Kinase Activity Using Scintillation Proximity Assay in 384-Well Format and Imaging Proximity Assay in 384- and 1536-Well Format , 2000, Journal of biomolecular screening.
[135] John C. Lee,et al. p38 MAP kinase: molecular target for the inhibition of pro-inflammatory cytokines. , 2001, Progress in medicinal chemistry.
[136] J. Adams,et al. Novel IKK inhibitors: β-carbolines , 2003 .
[137] Roger Bossé,et al. AlphaScreen kinase HTS platforms. , 2004, Current medicinal chemistry.
[138] G. Peters,et al. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. , 1996, Advances in cancer research.
[139] James R. Burke,et al. BMS-345541 Is a Highly Selective Inhibitor of IκB Kinase That Binds at an Allosteric Site of the Enzyme and Blocks NF-κB-dependent Transcription in Mice* , 2003, The Journal of Biological Chemistry.
[140] C. Landry,et al. Quantification of dynamic protein complexes using Renilla luciferase fragment complementation applied to protein kinase A activities in vivo , 2007, Proceedings of the National Academy of Sciences.
[141] J. Madwed,et al. Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate. , 2002, Journal of medicinal chemistry.
[142] L. Johnson,et al. Protein Kinase Inhibitors: Insights into Drug Design from Structure , 2004, Science.
[143] J. Boehm,et al. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases , 2003, Nature Reviews Drug Discovery.
[144] A. Manning,et al. Targeting JNK for therapeutic benefit: from junk to gold? , 2003, Nature Reviews Drug Discovery.
[145] T. Yue,et al. Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. , 1999, Circulation.
[146] A. Burgess,et al. Epidermal Growth Factor Receptor: Association of Extracellular Domain Negatively Regulates Intracellular Kinase Activation in the Absence of Ligand , 2003, Growth factors.
[147] P. Kennelly,et al. The detection of enzyme activity following sodium dodecyl sulfate-polyacrylamide gel electrophoresis. , 1998, Analytical biochemistry.
[148] Hiroshi Hirai,et al. Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases. , 2005, Current topics in medicinal chemistry.